{
    "ticker": "HROW",
    "name": "Harrow Health, Inc.",
    "description": "Harrow Health, Inc. is a healthcare company dedicated to providing innovative solutions in the field of ophthalmology. Founded in 2017 and based in Nashville, Tennessee, Harrow focuses on the development, manufacturing, and commercialization of specialty pharmaceuticals for eye care. The company\u2019s mission is to improve patient outcomes by providing effective, high-quality medications that address unmet needs in the ophthalmic marketplace. Harrow's flagship products include compounded formulations and FDA-approved sterile injectables, which are designed to treat a range of eye conditions such as glaucoma, dry eye, and ocular inflammation. By leveraging advanced technologies and fostering relationships with healthcare professionals, Harrow aims to enhance the way ophthalmic treatments are delivered. The company's commitment to innovation is evident in its continuous efforts to expand its product portfolio and improve existing therapies. Additionally, Harrow is actively involved in research and development to discover new treatment options and enhance patient care. As a leader in ophthalmic pharmaceuticals, Harrow Health strives to contribute to the advancement of eye care and ensure that patients receive the best possible therapies available.",
    "industry": [
        "Pharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Nashville, Tennessee, USA",
    "founded": "2017",
    "website": "https://www.harrowhealth.com",
    "ceo": "Mark L. Baum",
    "social_media": {
        "twitter": "https://twitter.com/HarrowHealth",
        "linkedin": "https://www.linkedin.com/company/harrow-health-inc/"
    },
    "investor_relations": "https://www.harrowhealth.com/investors",
    "key_executives": [
        {
            "name": "Mark L. Baum",
            "position": "CEO"
        },
        {
            "name": "Gregory L. P. K. Dempsey",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Ophthalmic Pharmaceuticals",
            "products": [
                "Compounded Formulations",
                "FDA-Approved Sterile Injectables"
            ]
        }
    ],
    "seo": {
        "meta_title": "Harrow Health, Inc. | Innovative Ophthalmic Pharmaceuticals",
        "meta_description": "Explore Harrow Health, Inc., a leader in ophthalmic pharmaceuticals dedicated to improving patient outcomes through innovative treatments and solutions.",
        "keywords": [
            "Harrow Health",
            "Ophthalmology",
            "Pharmaceuticals",
            "Eye Care",
            "Healthcare",
            "Innovative Treatments"
        ]
    },
    "faq": [
        {
            "question": "What does Harrow Health specialize in?",
            "answer": "Harrow Health specializes in ophthalmic pharmaceuticals, focusing on innovative treatments for eye care."
        },
        {
            "question": "Who is the CEO of Harrow Health?",
            "answer": "Mark L. Baum is the CEO of Harrow Health, Inc."
        },
        {
            "question": "Where is Harrow Health headquartered?",
            "answer": "Harrow Health is headquartered in Nashville, Tennessee, USA."
        },
        {
            "question": "What are Harrow's main products?",
            "answer": "Harrow's main products include compounded formulations and FDA-approved sterile injectables for ophthalmic use."
        },
        {
            "question": "When was Harrow Health founded?",
            "answer": "Harrow Health was founded in 2017."
        }
    ],
    "competitors": [
        "EYE",
        "TIVC",
        "NVCR"
    ],
    "related_stocks": [
        "AMGN",
        "ABBV",
        "GILD",
        "VRTX"
    ]
}